|
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
Dec 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
T cell dysfunctions in myelodysplastic syndromes |
Jan 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
May 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
Sep 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
Jan 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision‐making and treatment of myelodysplastic syndromes |
Oct 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
Oct 2023 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
